Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Triumph’s Gorgeous, Super-Affordable and Approachable New Street Motos Share a Heart But Not a Soul - 2Wedding trip Objections in the US
- 37 Odd Apparatuses to Make Your Party Stick Out!
- 44 astronauts are now on their path to the moon. Here’s what happens next
- 5Vote In favor of Your Favored Web-based Venture Stage
- Nations for Rock Climbing
- Moving Pool Highlights for 2024
- Paratroopers kill terrorist who threw rocks at Israeli citizens, soldiers near Ofra in West Bank
- Independence from the rat race for Recent college grads: Systems and Tips
- Dependable Savvy Locks to Update Your Home Security
- ISS astronauts spy airglow and dwarf galaxy | Space photo of the day for Jan. 13, 2026
- San Francisco sues 10 companies that make ultraprocessed food
- AstraZeneca to invest $2 billion as part of US manufacturing push
- Excited visitors for NASA's moon launch jockey for prime views
